Thijs van der Vaart1, André B Rietman1, Ellen Plasschaert1, Eric Legius1, Ype Elgersma1, Henriëtte A Moll2. 1. From the Departments of Neuroscience (T.v.d.V., Y.E.), Pediatrics (T.v.d.V., H.A.M.), and Neurology (A.B.R.), and ENCORE-Expertise Center for Neurodevelopmental Disorders (T.v.d.V., A.B.R., Y.E., H.A.M.), Erasmus MC: University Medical Centre, Rotterdam, the Netherlands; the Department of Human Genetics (E.P., E.L.), Catholic University Leuven; and the Centre for Human Genetics at University Hospital Leuven (E.P., E.L.), Belgium. 2. From the Departments of Neuroscience (T.v.d.V., Y.E.), Pediatrics (T.v.d.V., H.A.M.), and Neurology (A.B.R.), and ENCORE-Expertise Center for Neurodevelopmental Disorders (T.v.d.V., A.B.R., Y.E., H.A.M.), Erasmus MC: University Medical Centre, Rotterdam, the Netherlands; the Department of Human Genetics (E.P., E.L.), Catholic University Leuven; and the Centre for Human Genetics at University Hospital Leuven (E.P., E.L.), Belgium. h.a.moll@erasmusmc.nl.
Abstract
OBJECTIVE: To evaluate the appropriateness of cognitive and behavioral outcome measures in clinical trials in neurofibromatosis type 1 (NF1) by analyzing the degree of deficits compared to reference groups, test-retest reliability, and how scores correlate between outcome measures. METHODS: Data were analyzed from the Simvastatin for cognitive deficits and behavioral problems in patients with neurofibromatosis type 1 (NF1-SIMCODA) trial, a randomized placebo-controlled trial of simvastatin for cognitive deficits and behavioral problems in children with NF1. Outcome measures were compared with age-specific reference groups to identify domains of dysfunction. Pearson r was computed for before and after measurements within the placebo group to assess test-retest reliability. Principal component analysis was used to identify the internal structure in the outcome data. RESULTS: Strongest mean score deviations from the reference groups were observed for full-scale intelligence (-1.1 SD), Rey Complex Figure Test delayed recall (-2.0 SD), attention problems (-1.2 SD), and social problems (-1.1 SD). Long-term test-retest reliability were excellent for Wechsler scales (r > 0.88), but poor to moderate for other neuropsychological tests (r range 0.52-0.81) and Child Behavioral Checklist subscales (r range 0.40-0.79). The correlation structure revealed 2 strong components in the outcome measures behavior and cognition, with no correlation between these components. Scores on psychosocial quality of life correlate strongly with behavioral problems and less with cognitive deficits. CONCLUSIONS:Children with NF1 show distinct deficits in multiple domains. Many outcome measures showed weak test-retest correlations over the 1-year trial period. Cognitive and behavioral outcomes are complementary. This analysis demonstrates the need to include reliable outcome measures on a variety of cognitive and behavioral domains in clinical trials for NF1.
RCT Entities:
OBJECTIVE: To evaluate the appropriateness of cognitive and behavioral outcome measures in clinical trials in neurofibromatosis type 1 (NF1) by analyzing the degree of deficits compared to reference groups, test-retest reliability, and how scores correlate between outcome measures. METHODS: Data were analyzed from the Simvastatin for cognitive deficits and behavioral problems in patients with neurofibromatosis type 1 (NF1-SIMCODA) trial, a randomized placebo-controlled trial of simvastatin for cognitive deficits and behavioral problems in children with NF1. Outcome measures were compared with age-specific reference groups to identify domains of dysfunction. Pearson r was computed for before and after measurements within the placebo group to assess test-retest reliability. Principal component analysis was used to identify the internal structure in the outcome data. RESULTS: Strongest mean score deviations from the reference groups were observed for full-scale intelligence (-1.1 SD), Rey Complex Figure Test delayed recall (-2.0 SD), attention problems (-1.2 SD), and social problems (-1.1 SD). Long-term test-retest reliability were excellent for Wechsler scales (r > 0.88), but poor to moderate for other neuropsychological tests (r range 0.52-0.81) and Child Behavioral Checklist subscales (r range 0.40-0.79). The correlation structure revealed 2 strong components in the outcome measures behavior and cognition, with no correlation between these components. Scores on psychosocial quality of life correlate strongly with behavioral problems and less with cognitive deficits. CONCLUSIONS:Children with NF1 show distinct deficits in multiple domains. Many outcome measures showed weak test-retest correlations over the 1-year trial period. Cognitive and behavioral outcomes are complementary. This analysis demonstrates the need to include reliable outcome measures on a variety of cognitive and behavioral domains in clinical trials for NF1.
Authors: Weidong Li; Yijun Cui; Steven A Kushner; Robert A M Brown; J David Jentsch; Paul W Frankland; Tyrone D Cannon; Alcino J Silva Journal: Curr Biol Date: 2005-11-08 Impact factor: 10.834
Authors: Shruti Garg; Annukka Lehtonen; Susan M Huson; Richard Emsley; Dorothy Trump; D Gareth Evans; Jonathan Green Journal: Dev Med Child Neurol Date: 2012-11-16 Impact factor: 5.449
Authors: Maria T Acosta; Peter G Kardel; Karin S Walsh; Kenneth N Rosenbaum; Gerard A Gioia; Roger J Packer Journal: Pediatr Neurol Date: 2011-10 Impact factor: 3.372
Authors: Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby Journal: J Med Genet Date: 2006-11-14 Impact factor: 6.318
Authors: Lianne C Krab; Arja de Goede-Bolder; Femke K Aarsen; Saskia M F Pluijm; Marlies J Bouman; Jos N van der Geest; Maarten Lequin; Coriene E Catsman; Willem Frans M Arts; Steven A Kushner; Alcino J Silva; Chris I de Zeeuw; Henriëtte A Moll; Ype Elgersma Journal: JAMA Date: 2008-07-16 Impact factor: 56.272
Authors: David F Wozniak; Kelly A Diggs-Andrews; Sara Conyers; Carla M Yuede; Joshua T Dearborn; Jacquelyn A Brown; Kazuhiro Tokuda; Yukitoshi Izumi; Charles F Zorumski; David H Gutmann Journal: PLoS One Date: 2013-06-10 Impact factor: 3.240
Authors: Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne Journal: Neuropsychol Rev Date: 2018-08-11 Impact factor: 7.444
Authors: David A Stevenson; Lisa Schill; Lisa Schoyer; Brage S Andresen; Annette Bakker; Pinar Bayrak-Toydemir; Emma Burkitt-Wright; Kathryn Chatfield; Florent Elefteriou; Ype Elgersma; Michael J Fisher; David Franz; Bruce D Gelb; Anne Goriely; Karen W Gripp; Antonio Y Hardan; Kim M Keppler-Noreuil; Bronwyn Kerr; Bruce Korf; Chiara Leoni; Frank McCormick; Scott R Plotkin; Katherine A Rauen; Karlyne Reilly; Amy Roberts; Abby Sandler; Dawn Siegel; Karin Walsh; Brigitte C Widemann Journal: Am J Med Genet A Date: 2016-05-07 Impact factor: 2.802
Authors: Danielle M Glad; Christina L Casnar; Brianna D Yund; Kristin Lee; Bonita P Klein-Tasman Journal: J Dev Behav Pediatr Date: 2021 Oct-Nov 01 Impact factor: 2.225
Authors: Alejandro López-Juárez; Haley E Titus; Sadiq H Silbak; Joshua W Pressler; Tilat A Rizvi; Madeleine Bogard; Michael R Bennett; Georgianne Ciraolo; Michael T Williams; Charles V Vorhees; Nancy Ratner Journal: Cell Rep Date: 2017-04-18 Impact factor: 9.423
Authors: Jonathan M Payne; Stephen J C Hearps; Karin S Walsh; Iris Paltin; Belinda Barton; Nicole J Ullrich; Kristina M Haebich; David Coghill; Gerard A Gioia; Alan Cantor; Gary Cutter; James H Tonsgard; David Viskochil; Celiane Rey-Casserly; Elizabeth K Schorry; Joseph D Ackerson; Laura Klesse; Michael J Fisher; David H Gutmann; Tena Rosser; Roger J Packer; Bruce Korf; Maria T Acosta; Kathryn N North Journal: Ann Clin Transl Neurol Date: 2019-12-03 Impact factor: 4.511
Authors: Sarah C Borrie; Ellen Plasschaert; Zsuzsanna Callaerts-Vegh; Akihiko Yoshimura; Rudi D'Hooge; Ype Elgersma; Steven A Kushner; Eric Legius; Hilde Brems Journal: Mol Autism Date: 2021-07-26 Impact factor: 7.509